Condition: Non Small Cell Lung Cancer (NSCLC) · Sponsor: Wayshine Biopharm, Inc.
This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with C797S mutation or is newly diagnosed with CNS metastasis with EGFR Del19 or L858R mutation
This description comes directly from the study's public registry record.
lily Liu, MD · +8613818880308 · lily.liu@wayshinebiopharm.com
Wei Zhong, PhD · 1-951-547-4692 · wei.zhong@wayshinebiopharm.com
Always discuss trial participation with your own doctor first.
| Shanghai East Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07206498